<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13639">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381862</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000503649</org_study_id>
    <secondary_id>OHSU-SOL-06006-LM</secondary_id>
    <secondary_id>OHSU-IRB-2302</secondary_id>
    <nct_id>NCT00381862</nct_id>
  </id_info>
  <brief_title>Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant &amp; Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting</brief_title>
  <official_title>A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and
      vomiting in patients receiving chemotherapy.

      PURPOSE: This phase II trial is studying how well giving aprepitant together with
      palonosetron and dexamethasone works in preventing nausea and vomiting caused by
      chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the efficacy, in terms of nausea and vomiting control, of aprepitant,
           palonosetron hydrochloride, and dexamethasone, in preventing chemotherapy-induced
           nausea and vomiting in patients receiving FOLFOX or FOLFIRI chemotherapy for metastatic
           colorectal cancer.

      Secondary

        -  Assess the percentage of patients with no emesis and no rescue therapy when treated
           with aprepitant, palonosetron hydrochloride, and dexamethasone during repeated courses
           of FOLFOX or FOLFIRI chemotherapy.

        -  Assess the effects of aprepitant on nausea, appetite, taste changes (via visual
           analogue scale), nutritional intake, and mucositis in these patients.

        -  Assess the safety of this regimen in these patients.

      OUTLINE: This is an open-label, multicenter study.

      Beginning 1 hour prior to the initiation of chemotherapy on day 1, patients receive oral
      aprepitant on days 1-3, oral dexamethasone on days 1-4, and palonosetron hydrochloride IV on
      day 1.

      Nausea is assessed daily for up to 4 courses of chemotherapy.

      Quality of life is assessed at baseline.

      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With no Emesis and no Rescue Therapy During Repeated Courses of Chemotherapy</measure>
    <time_frame>Duration of time that the patient is on study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Aprepitant on Nausea, Appetite, Taste Changes, (Via Visual Analogue Scale [VAS]), Nutritional Intake, and Mucositis in the Colorectal Cancer (CRC) Population.</measure>
    <time_frame>Duration of time the patient is on study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Safety of the Combination of Aprepitant, Palonosetron, and Dexamethasone in the Colorectal Cancer(CRC) Population in the First and Subsequent Cycles of Chemotherapy.</measure>
    <time_frame>Duration of time patient is on study</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With no Emesis and no Rescue Therapy Within 5 Days of the First Course of Chemotherapy</measure>
    <time_frame>within 5 days of chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
    <other_name>Emend</other_name>
    <other_name>MK-869</other_name>
    <other_name>L-758,298</other_name>
    <other_name>L-754,030</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>as per institutional standard of care</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>as per institutional standard of care</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
    <other_name>Trade names: Camptosar®</other_name>
    <other_name>Other names: Camptothecin-11, CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>as per institutional standard of care</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
    <other_name>Generic Name: Leucovorin</other_name>
    <other_name>Other Names: Citrovorum Factor, Folinic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>as per institutional standard of care</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
    <other_name>Trade Name: Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron hydrochloride</intervention_name>
    <description>Palonosetron 0.25 mg IV push on day 1 only.</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>baseline</description>
    <arm_group_label>Aprepitant and Palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of colorectal cancer

          -  Metastatic disease

          -  Scheduled to receive 1 of the following chemotherapy regimens*:

               -  FOLFOX 4 (oxaliplatin, fluorouracil, leucovorin calcium)

               -  FOLFOX 6

               -  FOLFOX 7

               -  FOLFIRI (irinotecan hydrochloride, fluorouracil, leucovorin calcium) NOTE:
                  *Regimens may also include cetuximab or bevacizumab

          -  No emesis and no requirement for antiemetic agents within 48 hours prior to beginning
             chemotherapy

               -  Single-agent benzodiazepines as a hypnotic allowed

          -  No chronic nausea

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy &gt; 4 months

          -  White Blood Cell(WBC)count &gt; 3,000/mm^³

          -  Absolute neutrophil count (ANC) &gt; 1,500/mm^³

          -  Platelet count &gt; 100,000/mm^³

          -  Bilirubin ≤ 2.5 times upper limit of normal (ULN) (&lt; 5 times ULN if liver metastases
             present)

          -  Creatinine ≤ 1.5 times ULN

          -  Aspartate aminotransferase(AST) or Alanine aminotransferase (ALT) ≤ 2.5 times ULN (&lt;
             5 times ULN if liver metastases present)

          -  Able to swallow tablets and capsules

          -  No known sensitivity to aprepitant, palonosetron hydrochloride, or dexamethasone

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No history of consuming ≥ 5 alcoholic drinks/day within the past year

          -  No concurrent illness requiring systemic corticosteroids other than planned
             dexamethasone during study treatment

          -  No clinical signs of active systemic infection involving the gastrointestinal tract

          -  No active bowel obstruction

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy &gt; Hesketh level 3

               -  Prior fluorouracil with or without leucovorin calcium or capecitabine allowed

          -  At least 30 days since prior investigational drugs

          -  At least 14 days since prior neurokinin-1 antagonists

          -  Concurrent hydrocortisone at physiologic replacement doses (≤ 30 mg/day) allowed

          -  No concurrent chronic antiemetic agents

          -  Concurrent hypnotics allowed

          -  Concurrent rescue antiemetics allowed
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Bubalo, PharmD, BCPS, BCOP</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Josephs/Cander Hospital</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Hilo</city>
        <state>Hawaii</state>
        <zip>86720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas A &amp; M university / Scott and White Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 9, 2016</lastchanged_date>
  <firstreceived_date>September 26, 2006</firstreceived_date>
  <firstreceived_results_date>June 10, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aprepitant and Palonosetron</title>
          <description>Aprepitant: 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
Palonosetron: 0.25 mg IV push on day 1 only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aprepitant and Palonosetron</title>
          <description>Aprepitant: 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
Palonosetron: 0.25 mg IV push on day 1 only</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55" spread="11.728"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.</title>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant and Palonosetron</title>
            <description>Aprepitant: 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
Palonosetron: 0.25 mg IV push on day 1 only</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With no Emesis and no Rescue Therapy During Repeated Courses of Chemotherapy</title>
        <time_frame>Duration of time that the patient is on study</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Aprepitant on Nausea, Appetite, Taste Changes, (Via Visual Analogue Scale [VAS]), Nutritional Intake, and Mucositis in the Colorectal Cancer (CRC) Population.</title>
        <time_frame>Duration of time the patient is on study</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Safety of the Combination of Aprepitant, Palonosetron, and Dexamethasone in the Colorectal Cancer(CRC) Population in the First and Subsequent Cycles of Chemotherapy.</title>
        <time_frame>Duration of time patient is on study</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With no Emesis and no Rescue Therapy Within 5 Days of the First Course of Chemotherapy</title>
        <time_frame>within 5 days of chemotherapy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aprepitant and Palonosetron</title>
          <description>Aprepitant: 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
Palonosetron: 0.25 mg IV push on day 1 only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>GI Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="13" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Mental Status</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Venous Thromboembolism (VTE)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heartburn/ Gastroesophageal Reflux Disease (GERD)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy-Cold Related</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Neuropathy-Peripheral/Sensory</sub_title>
                <counts group_id="E1" events="18" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Bubalo, PharmD, BCPS, BCOP</name_or_title>
      <organization>OHSU Knight Cancer Institute</organization>
      <phone>503-494-1080</phone>
      <email>bubaloj@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
